Press Releases

   

Date Title PDF HTML
7/30/2010 Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference
7/29/2010 ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
7/29/2010 Anadys Pharmaceuticals Reports Second Quarter 2010 Financial Results and Highlights
7/22/2010 Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results
5/26/2010 Anadys Retains Lazard as Strategic Advisor
5/26/2010 Anadys Pharmaceuticals Announces $12.5 Million Registered Direct Offering
5/21/2010 Anadys Announces Completed 12-Week Results From Phase II Combination Study
4/27/2010 Anadys Pharmaceuticals Reports First Quarter 2010 Financial Results and Highlights
4/20/2010 Anadys Pharmaceuticals to Report First Quarter 2010 Financial Results
4/15/2010 72% of Patients Receiving ANA598 in Phase II Combination Study with Interferon and Ribavirin Achieve Undetectable Levels of Virus at Week Eight
3/29/2010 Anadys Announces Two ANA598 Presentations to be Made at the EASL Annual Meeting in April
3/25/2010 Anadys Pharamaceuticals to Present at the CanAccord Adams Hepatitis C Conference
3/9/2010 Anadys Pharamaceuticals to Present at the ROTH OC Stock Growth Conference
3/1/2010 Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
2/24/2010 Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results and Highlights
2/24/2010 ANA598 Demonstrates 73% cEVR in Combination with Interferon and Ribavirin
2/17/2010 Anadys Pharamaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
2/2/2010 Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
1/22/2010 ANADYS PHARMACEUTICALS PROVIDES PROGRESS UPDATE